CYP2C19 Genotype-Guided Antiplatelet Therapy in Stroke Patients-Is It Ready for Prime Time?
作者信息
Shao Danwei, Mosha Joyce, Patel Rajiv C, Lee Craig R, Stouffer George A
机构信息
Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, Chapel Hill, USA.
Division of Cardiology and McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, 27599-7075, USA.
出版信息
Cardiovasc Drugs Ther. 2024 Dec;38(6):1079-1081. doi: 10.1007/s10557-024-07627-4. Epub 2024 Sep 4.
Abstract
摘要
相似文献
1
CYP2C19 Genotype-Guided Antiplatelet Therapy in Stroke Patients-Is It Ready for Prime Time?CYP2C19基因指导的中风患者抗血小板治疗——它是否已准备好进入黄金时代？
Cardiovasc Drugs Ther. 2024 Dec;38(6):1079-1081. doi: 10.1007/s10557-024-07627-4. Epub 2024 Sep 4.
2
Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.中国急性小缺血性卒中和高危短暂性脑缺血发作患者 CYP2C19 基因指导抗血小板治疗的成本效果分析。
Br J Clin Pharmacol. 2024 Feb;90(2):483-492. doi: 10.1111/bcp.15921. Epub 2023 Nov 8.
3
The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.CYP2C19 基因指导的抗血小板治疗与急性冠脉综合征或经皮冠状动脉介入治疗患者常规抗血小板治疗的疗效和安全性的比较：随机对照试验的荟萃分析。
Platelets. 2020 Nov 16;31(8):971-980. doi: 10.1080/09537104.2020.1780205. Epub 2020 Jun 16.
4
Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence.CYP2C19基因指导的抗血小板治疗在心血管和脑血管不良事件风险患者中的临床应用：新证据综述
Pharmgenomics Pers Med. 2020 Jul 27;13:239-252. doi: 10.2147/PGPM.S231475. eCollection 2020.
5
The role of genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.基因分型在缺血性卒中和短暂性脑缺血发作后指导抗血小板治疗中的作用。
Expert Rev Clin Pharmacol. 2022 Jul;15(7):811-825. doi: 10.1080/17512433.2022.2108401. Epub 2022 Aug 4.
6
CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.CYP2C19基因分型指导的抗血小板治疗与接受神经介入手术患者的临床结局
Clin Transl Sci. 2025 Jan;18(1):e70131. doi: 10.1111/cts.70131.
7
Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.老年脑卒中患者治疗中CYP2C19基因多态性与氯吡格雷的相关性
BMC Neurol. 2021 Mar 9;21(1):104. doi: 10.1186/s12883-021-02127-6.
8
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.评估在抗血小板治疗选择中进行 CYP2C19 基因分型的患者中 CYP2C19 基因型数据的可重用程度。
Genet Med. 2020 Nov;22(11):1898-1902. doi: 10.1038/s41436-020-0894-2. Epub 2020 Jul 17.
9
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.CYP2C19*17 等位基因对经皮冠状动脉介入治疗后接受基于基因型的抗血小板治疗患者结局的影响。
Clin Pharmacol Ther. 2021 Mar;109(3):705-715. doi: 10.1002/cpt.2039. Epub 2020 Oct 2.
10
Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.CYP2C19 基因指导的抗血小板治疗与急性冠状动脉综合征患者普遍使用抗血小板药物的经济学评价：系统评价。
J Cardiovasc Pharmacol Ther. 2020 May;25(3):201-211. doi: 10.1177/1074248420902298. Epub 2020 Feb 6.
本文引用的文献
1
Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association.基因检测用于口服 P2Y12 抑制剂治疗：美国心脏协会的科学声明。
Circulation. 2024 Aug 6;150(6):e129-e150. doi: 10.1161/CIR.0000000000001257. Epub 2024 Jun 20.
2
Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies.CYP2C19基因分型对卒中或短暂性脑缺血发作患者氯吡格雷抗血小板治疗疗效和安全性的影响：非东亚研究的最新系统评价和荟萃分析
Cardiovasc Drugs Ther. 2024 Dec;38(6):1397-1407. doi: 10.1007/s10557-023-07534-0. Epub 2023 Dec 1.
3
Evaluation of race and ethnicity disparities in outcome studies of genotype-guided antiplatelet therapy.基因分型指导抗血小板治疗结局研究中的种族和民族差异评估。
Front Cardiovasc Med. 2022 Aug 23;9:991646. doi: 10.3389/fcvm.2022.991646. eCollection 2022.
4
The role of genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.基因分型在缺血性卒中和短暂性脑缺血发作后指导抗血小板治疗中的作用。
Expert Rev Clin Pharmacol. 2022 Jul;15(7):811-825. doi: 10.1080/17512433.2022.2108401. Epub 2022 Aug 4.
5
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.临床药物遗传学实施联盟 CYP2C19 基因型和氯吡格雷治疗指南：2022 更新版。
Clin Pharmacol Ther. 2022 Nov;112(5):959-967. doi: 10.1002/cpt.2526. Epub 2022 Feb 8.
6
Ticagrelor versus Clopidogrel in Loss-of-Function Carriers with Stroke or TIA.替卡格雷与氯吡格雷在伴有卒中和 TIA 的功能丧失型携带者中的比较。
N Engl J Med. 2021 Dec 30;385(27):2520-2530. doi: 10.1056/NEJMoa2111749. Epub 2021 Oct 28.
7
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association.《2021年卒中与短暂性脑缺血发作患者卒中预防指南：美国心脏协会/美国卒中协会指南》
Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375. Epub 2021 May 24.
8
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.CYP2C19 基因分型指导急性冠状动脉综合征或经皮冠状动脉介入治疗患者抗血小板治疗的临床实用性。
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi: 10.1161/ATVBAHA.118.311963.
9
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.遗传多态性与氯吡格雷对急性缺血性卒中和短暂性脑缺血发作的疗效：系统评价和荟萃分析。
Circulation. 2017 Jan 3;135(1):21-33. doi: 10.1161/CIRCULATIONAHA.116.024913. Epub 2016 Nov 2.
Zotero 插件